Novel Therapy for Difficult Airway Disorder – Breakthrough Treatment
- Precigen's Papzimeos has received FDA approval, marking a significant breakthrough in the treatment of Recurrent Respiratory papillomatosis (RRP).
- The therapy utilizes a non-replicating adenoviral vector from Precigen's AdenoVerse platform. This vector delivers a fusion antigen comprised of fragments from HPV 6 and 11 proteins.
- * Addresses the Root Cause: Unlike surgery, Papzimeos targets the underlying viral cause of RRP.
Papzimeos: A New Hope for Recurrent Respiratory Papillomatosis (RRP) Patients
Precigen’s Papzimeos has received FDA approval, marking a significant breakthrough in the treatment of Recurrent Respiratory papillomatosis (RRP). This innovative immunotherapy offers a potential alternative to the repeated surgeries currently used to manage the condition, aiming to address the root cause of the disease rather than just its symptoms.
How papzimeos Works:
The therapy utilizes a non-replicating adenoviral vector from Precigen’s AdenoVerse platform. This vector delivers a fusion antigen comprised of fragments from HPV 6 and 11 proteins. This process essentially “teaches” the body’s T cells to recognize and target the virus, triggering an immune response. Clinical trials have demonstrated a significant expansion of HPV-specific T cells in patients who responded to the treatment, confirming triumphant immune reprogramming.
Key Features & Benefits:
* Addresses the Root Cause: Unlike surgery, Papzimeos targets the underlying viral cause of RRP.
* Short-Course Dosing: The treatment involves four subcutaneous injections administered over 12 weeks.
* Durable Immune Control: Designed to provide long-lasting control of the disease, potentially eliminating the need for repeated surgeries.
* High Response Rate: A study conducted at the National Institutes of Health showed that over half of the 35 participants achieved complete response, requiring no surgeries for 12 months post-treatment.
* long-Term Remission: Most participants followed for two years remained papilloma-free, indicating long-term immune memory.
* Well-Tolerated: The therapy demonstrated a favorable safety profile with no dose-limiting toxicities and mostly mild, typical immune activation side effects (injection site reactions, fever, chills, fatigue). While rare risks like thrombotic events are noted in the FDA label,the overall safety profile is better than that of repeated surgeries.
According to Helen Sabzevari, CEO of Precigen, “this is not just symptom management, it’s the first therapy designed to address the root cause of RRP.”
Why this approval is important:
* Mechanistic Precision: Directly targets HPV 6 and 11 proteins, the drivers of RRP.
* Vector Design: Utilizes a proprietary AdenoVerse platform for effective antigen delivery.
This approval represents a dramatic shift in the treatment landscape for RRP,offering patients the potential for sustained remission and a considerably improved quality of life.